Clinical Policy: Bexarotene (Targretin Capsules, Gel)

Reference Number: CP.PHAR.75
Effective Date: 09.01.11
Last Review Date: 05.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Bexarotene (Targretin®) is a retinoid X receptor activator.

FDA Approved Indication(s)
Targretin capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy.

Targretin gel is indicated for the topical treatment of cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Targretin is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Cutaneous T-Cell Lymphoma (must meet all):
      1. Request is for bexarotene capsules;
      2. Diagnosis of CTCL (see Appendix D for CTCL subtypes);
      3. Prescribed by or in consultation with an oncologist;
      4. Age ≥ 18 years;
      5. Request meets one of the following (a or b):*
         a. Dose does not exceed 400 mg/m² per day;
         b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
   *Prescribed regimen must be FDA-approved or recommended by NCCN

   Approval duration:
   Medicaid/HIM – 6 months
   Commercial – Length of Benefit

   B. Primary Cutaneous Lymphomas of the Skin (must meet all):
      1. Request is for Targretin gel;
      2. Diagnosis of CTCL or cutaneous B-cell lymphoma (CBCL) (see Appendix D for CTCL and CBCL subtypes);
3. Prescribed by or in consultation with an oncologist;
4. Age ≥ 18 years;
5. Disease manifestation is localized to skin only;
6. Request meets one of the following (a of b):*
   a. Dose does not exceed application of four times per day;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Medicaid/HIM – 6 months
Commercial – Length of Benefit

C. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. Primary Cutaneous Lymphoma (must meet all):
   1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Targretin for a covered indication, and has received this medication for at least 30 days;
   2. Member is responding positively to therapy;
   3. If request is for a dose increase, request meets one of the following (a or b):*
      a. Bexarotene capsules: New dose does not exceed 400 mg/m² per day;
      b. Bexarotene gel: New dose does not exceed application of four times per day;
      c. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Medicaid/HIM – 6 months
Commercial – Length of Benefit

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
      Approval duration: Duration of request or 6 months (whichever is less); or
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies –
IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
- ALCL: anaplastic large cell lymphoma
- ATLL: adult T-cell leukemia/lymphoma
- C-ALCL: primary cutaneous anaplastic large cell lymphoma
- CBCL: cutaneous B-cell lymphoma
- CTCL: cutaneous T-cell lymphoma
- EBV: Epstein-Barr virus
- FDA: Food and Drug Administration
- LyP: lymphomatoid papulosis
- MF: mycosis fungoides
- NK cells: natural killer cells
- RAR: retinoid acid receptor
- RXR: retinoic X receptors

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s): Pregnancy; known hypersensitivity to bexarotene
- Boxed warning(s): Birth defects

Appendix D: WHO-EORTC Classification of primary cutaneous lymphomas
- CTCL
  - Mycosis fungoides (MF)
  - MF variants and subtypes
    - Folliculotrop MF
    - Pagetoid reticulosis
    - Granulomatous slack skin
  - Sezary syndrome
  - Adult T-cell leukemia/lymphoma (ATLL)
  - Primary cutaneous CD30+ lymphoproliferative disorders
    - Primary cutaneous anaplastic large cell lymphoma (C-ALCL)
    - Lymphomatoid papulosis (LyP)
  - Subcutaneous panniculitis-like T-cell lymphoma
  - Extranodal NK*/T-cell lymphoma, nasal type
  - Chronic active EBV infection
  - Primary cutaneous peripheral T-cell lymphoma, not otherwise specified
  - Primary cutaneous peripheral T-cell lymphoma, rare subtypes
    - Primary cutaneous gamma/delta T-cell lymphoma
    - Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma (provisional)
  - Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (provisional)
  - Primary cutaneous acral CD8+ T-cell lymphoma (provisional)
- CBCL
  - primary cutaneous marginal zone lymphoma
V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTCL</td>
<td>Oral 300-400 mg/m²/day PO</td>
<td>Oral 400 mg/m²/day</td>
</tr>
<tr>
<td></td>
<td>Topical</td>
<td>Topical Four times daily</td>
</tr>
<tr>
<td></td>
<td>Initially applied once every other day for the first week. The application frequency should be increased at weekly intervals to once daily, then twice daily, then three times daily and finally four times daily according to individual lesion tolerance</td>
<td></td>
</tr>
</tbody>
</table>

VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bexarotene capsules (Targretin)</td>
<td>Capsules: 75 mg</td>
</tr>
<tr>
<td>Bexarotene 1% gel (Targretin)</td>
<td>Gel: 600 mg active bexarotene per 600 g</td>
</tr>
</tbody>
</table>

VII. References
Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy converted to new template. Removed criteria regarding TGL levels, pancreatic risk factors, liver enzymes, bilirubin and concurrent gemfibrozil administration as they are not contraindications or absolute reason to discontinue per PI. Approval periods, initial/continued, are retained at 3 months/3 months. Subtypes of cutaneous T-cell lymphoma are added at Appendix B, drawing from WHO-EORTC categories presented in Willenze 2005. NCCN compendial uses are added.</td>
<td>06.16</td>
<td>07.16</td>
</tr>
<tr>
<td>Hypersensitivity precaution and reasons to discontinue removed. Added dosing information. Efficacy statement added to continuation criteria. Approval periods lengthened from 3/3 to 6/12 months.</td>
<td>06.17</td>
<td>07.17</td>
</tr>
<tr>
<td>2Q 2018 annual review: Commercial and HIM lines of business added; added age; summarized NCCN and FDA approved uses for improved clarity; added specialist involvement in care; added continuity of care statement; references reviewed and updated.</td>
<td>02.13.18</td>
<td>05.18</td>
</tr>
<tr>
<td>2Q 2019 annual review: no significant changes; references reviewed and updated.</td>
<td>12.19.19</td>
<td>05.19</td>
</tr>
<tr>
<td>2Q 2020 annual review: added bexarotene gel formulation and criteria; updated appendix D primary cutaneous lymphoma classification; references reviewed and updated.</td>
<td>03.04.20</td>
<td>05.20</td>
</tr>
</tbody>
</table>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.
This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2011 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.